ストックスクリーナーアプリを入手
1.04
0.97%
0.01
前日終値:
$1.03
開ける：
$1.05
24時間の取引高:
132.54K
Relative Volume:
0.43
時価総額：
$58.83M
収益：
$3.67M
当期純損益:
$-13.83M
株価収益率:
-3.7143
EPS:
-0.28
ネットキャッシュフロー:
$-10.79M
1週間 パフォーマンス:
+0.97%
1か月 パフォーマンス:
-8.77%
6か月 パフォーマンス:
+71.22%
1年 パフォーマンス:
+1.96%
1日の値動き範囲:
$1.01
$1.05
1週間の範囲:
$0.9167
$1.06
52週間の値動き範囲:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
ICCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.04 | 60.37M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Icecure Medical Ltd (ICCM) 最新ニュース
IceCure Medical’s Shareholders Approve Key Agenda Items at Special Meeting - TipRanks
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - marketscreener.com
FY2025 EPS Estimates for IceCure Medical Boosted by Analyst - Defense World
IceCure Receives High Level of Interest from Breast Surgeons at - GuruFocus
Breast Cancer Treatment Breakthrough: Surgeons Rally Behind IceCure's Freezing Technology as FDA Approval Nears - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Shares Acquired by Geode Capital Management LLC - Defense World
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America - Barchart.com
IceCure Medical reports on FDA meeting for ProSense Cryoablation - TipRanks
ICCM Advances ProSense Approval with FDA Interface | ICCM Stock News - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Pat - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer - PR Newswire
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - GuruFocus
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems - marketscreener.com
Comparing Biotricity (NASDAQ:BTCY) and IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - StreetInsider
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation | ICCM Stock News - GuruFocus
IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell? - Defense World
IceCure Medical Announces Special Shareholder Meeting for May 2025 - TipRanks
FY2027 EPS Estimates for IceCure Medical Reduced by Analyst - Defense World
IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright - Defense World
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com
IceCure Medical Reports Growth and Awaits FDA Decision - TipRanks
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges - TipRanks
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PR Newswire
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses By Investing.com - Investing.com South Africa
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses - Investing.com
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - StreetInsider.com
Earnings Outlook For Icecure Medical - Benzinga
IceCure Medical aims to bring cold cancer treatment to Vietnam - Mugglehead Magazine
IceCure Medical (ICCM) Projected to Post Earnings on Thursday - Defense World
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - The Malaysian Reserve
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Res - GuruFocus
IceCure reports high efficacy in kidney tumor cryoablation study By Investing.com - Investing.com South Africa
IceCure reports high efficacy in kidney tumor cryoablation study - Investing.com India
IceCure Medical Earnings: Cryoablation Pioneer Reports 2024 Results March 27 - Stock Titan
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - The Malaysian Reserve
Icecure Medical Ltd (ICCM) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
0.22%
大文字化:
|
ボリューム (24 時間):